

---

**Sofosbuvir – Nutzenbewertung gemäß § 35a SGB V [Sofosbuvir: benefit assessment according to § 35a Social Code Book V (dossier assessment)]**

*IQWiG*

---

**Record Status**

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

**Citation**

IQWiG. Sofosbuvir – Nutzenbewertung gemäß § 35a SGB V. [Sofosbuvir: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 219. 2014

**Final publication URL**

[https://www.iqwig.de/download/A14-05\\_Sofosbuvir\\_Nutzenbewertung-35a-SGB-V.pdf](https://www.iqwig.de/download/A14-05_Sofosbuvir_Nutzenbewertung-35a-SGB-V.pdf)

**Indexing Status**

Subject indexing assigned by CRD

**MeSH**

Humans; Uridine Monophosphate; Hepatitis C, Chronic

**Language Published**

German

**Country of organisation**

Germany

**English summary**

There is no English language summary available.

**Address for correspondence**

IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1  
Email: [berichte@iqwig.de](mailto:berichte@iqwig.de)

**AccessionNumber**

32014000713

**Date abstract record published**

04/07/2014